On October 21, 2021, Xilio Therapeutics, Inc., a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, announced the pricing of its initial public offering of 7,353,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $117.6 million, before underwriting discounts and commissions and offering expenses payable by Xilio. Additionally, the company has granted the underwriters a 30-day option to purchase up to 1,102,950 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Xilio Therapeutics' common stock began trading on the Nasdaq Global Select Market under the ticker symbol “XLO” on October 22, 2021.

The WilmerHale team advising Xilio Therapeutics in its initial public offering was led by Cynthia Mazareas and Molly Fox, and included Stephanie Leopold, Ryan Brewer and Milan Kumar.